ID   LC-1/sq
AC   CVCL_3008
SY   LC-1 sq; LC-1-sq; LC-1Sq; LC1/Sq; LC1-Sq; LC1-sq; LC1sq; Lc1sq; LC1SQ; Lung cancer-1/squamous; LC-1; LC1
DR   CLO; CLO_0037019
DR   CLO; CLO_0050045
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 927
DR   BioSample; SAMN03471667
DR   cancercelllines; CVCL_3008
DR   Cell_Model_Passport; SIDM00300
DR   CGH-DB; 188-1
DR   CGH-DB; 9178-4
DR   Cosmic; 713858
DR   Cosmic; 801579
DR   Cosmic; 844843
DR   Cosmic; 876169
DR   Cosmic; 889102
DR   Cosmic; 917979
DR   Cosmic; 929146
DR   Cosmic; 932926
DR   Cosmic; 1219072
DR   Cosmic; 1239906
DR   Cosmic; 2668326
DR   Cosmic-CLP; 1298223
DR   DepMap; ACH-002156
DR   EGA; EGAS00001000978
DR   GDSC; 1298223
DR   GEO; GSM784280
DR   GEO; GSM827201
DR   GEO; GSM1374618
DR   GEO; GSM1670042
DR   IARC_TP53; 2382
DR   JCRB; JCRB0258
DR   LINCS_LDP; LCL-1586
DR   PharmacoDB; LC1sq_828_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3008
DR   RCB; RCB0455
DR   Wikidata; Q54902121
RX   PubMed=1917142;
RX   PubMed=8348978;
RX   PubMed=9023415;
RX   PubMed=9538136;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=14581340;
RX   PubMed=15185009;
RX   PubMed=15746151;
RX   PubMed=19472407;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=24002593;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 64.6 hours (PubMed=1917142); ~75 hours (Note=Lot 11122004) (JCRB=JCRB0258).
CC   HLA typing: A*11,24:02; B*44:03:01; C*12:03,16:01 (PubMed=9023415).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Arg1475Ter (c.4423C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.33%; Native American=0%; East Asian, North=91.84%; East Asian, South=7.55%; South Asian=0.28%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): Cosmic-CLP; JCRB; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,13
ST   D16S539: 9
ST   D5S818: 12,13
ST   D7S820: 12
ST   TH01: 7,9
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 34
//
RX   PubMed=1917142; DOI=10.1002/ijc.2910490322;
RA   Itoh H., Kataoka H., Koita H., Nabeshima K., Inoue T., Kangawa K.,
RA   Koono M.;
RT   "Establishment of a new human cancer cell line secreting protease
RT   nexin-II/amyloid beta protein precursor derived from squamous-cell
RT   carcinoma of lung.";
RL   Int. J. Cancer 49:436-443(1991).
//
RX   PubMed=8348978; DOI=10.1016/0014-5793(93)80946-R;
RA   Kataoka H., Seguchi K., Inoue T., Koono M.;
RT   "Properties of alpha 1-antitrypsin secreted by human adenocarcinoma
RT   cell lines.";
RL   FEBS Lett. 328:291-295(1993).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9538136; DOI=10.3892/ijo.12.5.1103;
RA   Takaki T., Hiraki A., Uenaka A., Gomi S., Itoh K., Udono H.,
RA   Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.;
RT   "Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-
RT   3 peptide recognized by cytotoxic T lymphocytes.";
RL   Int. J. Oncol. 12:1103-1109(1998).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=14581340;
RA   Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.;
RT   "TERC identified as a probable target within the 3q26 amplicon that is
RT   detected frequently in non-small cell lung cancers.";
RL   Clin. Cancer Res. 9:4705-4713(2003).
//
RX   PubMed=15185009; DOI=10.1007/s00262-004-0533-9;
RA   Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H.,
RA   Motohashi S., Yokoi S., Hiroshima K., Tagawa M., Nakayama T.,
RA   Fujisawa T.;
RT   "Correlation between interleukin 6 production and tumor proliferation
RT   in non-small cell lung cancer.";
RL   Cancer Immunol. Immunother. 53:786-792(2004).
//
RX   PubMed=15746151; DOI=10.1093/hmg/ddi092;
RA   Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in
RT   non-small cell lung cancers.";
RL   Hum. Mol. Genet. 14:997-1007(2005).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=24002593; DOI=10.1038/bjc.2013.452;
RA   Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.;
RT   "Gene-expression data integration to squamous cell lung cancer
RT   subtypes reveals drug sensitivity.";
RL   Br. J. Cancer 109:1599-1608(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//